VERTEX PHARMACEUTICALS INC / MA
VRTXAPI behind this page
VRTX FY 2025 request
Playground key active
/api/financials?ticker=VRTX&year=2025&quarter=4&full_year_mode=true
Pick an endpoint and run the request.Income Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Revenue | 12,001.3 | 11,020.1 | +8.9% |
Show Product Lines breakouts |
|||
| ALYFTREK | 837.8 | — | — |
| CASGEVY | 115.8 | 10 | +1058.0% |
| JOURNAVX | 59.6 | — | — |
| Manufactured Product Other | 820.1 | 781.5 | +4.9% |
| Other revenues | 30.7 | — | — |
| Product | 11,970.6 | 11,020.1 | +8.6% |
| Product · Accumulated Translation Adjustment | -73.3 | 35.7 | -305.3% |
| TRIKAFTA/KAFTRIO | 10,312.7 | 10,238.6 | +0.7% |
Show Business Segments breakouts |
|||
| Pharmaceuticals | 12,001.3 | 11,020.1 | +8.9% |
Show Geography breakouts |
|||
| Europe | 3,460.3 | 3,453.9 | +0.2% |
| Other | 992.4 | 881.3 | +12.6% |
| Total revenues outside of the United States | 4,452.7 | 4,335.2 | +2.7% |
| US | 7,548.6 | 6,684.9 | +12.9% |
| Cost of Revenue | 1,651.3 | 1,530.5 | +7.9% |
Show Product Lines breakouts |
|||
| Product · Pharmaceuticals | 601.5 | 516.3 | +16.5% |
| Royalty · Pharmaceuticals | 1,049.8 | 1,014.2 | +3.5% |
Show Collaborative Arrangements by Agreement [Axis] breakouts |
|||
| CRISPR JDCA | 146.8 | 73.5 | +99.7% |
| Research And Development Expense Excluding Acquired In Process Cost | 3,909.5 | 3,630.3 | +7.7% |
| Research And Development Asset Acquired Other Than Through Business Combination Written Off | 133 | 4,628.4 | -97.1% |
Show Business Segments breakouts |
|||
| Pharmaceuticals | 133 | 4,628.4 | -97.1% |
Show Collaborative Arrangements by Agreement [Axis] breakouts |
|||
| Additional In-License Agreements and Other Arrangements | 145.5 | 95.2 | +52.8% |
| Selling, General & Administrative | 1,753.1 | 1,464.3 | +19.7% |
Show Asset Acquisition breakouts |
|||
| Alpine Immune Sciences Inc · Unvested Equity Awards | 32.6 | — | — |
| Impairment Of Intangible Assets Indefinitelived Excluding Goodwill | 379 | — | — |
Show Business Segments breakouts |
|||
| Pharmaceuticals | 379 | — | — |
| Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | 2.1 | -0.5 | +520.0% |
| Total Costs & Expenses | 7,828 | 11,253 | -30.4% |
| Operating Income | 4,173.3 | -232.9 | +1891.9% |
| Investment Income Interest And Dividend | 490.9 | 598.1 | -17.9% |
Show Business Segments breakouts |
|||
| Pharmaceuticals | 490.9 | 598.1 | -17.9% |
| Interest Expense | -13.3 | -30.6 | +56.5% |
| Other Non-Operating Income (Expense) | -7.7 | -86.1 | +91.1% |
Show Equity Components breakouts |
|||
| Accumulated Translation Adjustment · Foreign Exchange Forward | -34.7 | 11.7 | -396.6% |
| Income Before Taxes | 4,643.2 | 248.5 | +1768.5% |
| Income Tax Expense (Benefit) | 690 | 784.1 | -12.0% |
Show Business Segments breakouts |
|||
| Pharmaceuticals | 690 | 784.1 | -12.0% |
| Net Income | 3,953.2 | -535.6 | +838.1% |
Show Business Segments breakouts |
|||
| Pharmaceuticals | 3,953.2 | -535.6 | +838.1% |
Show Equity Components breakouts |
|||
| Retained Earnings | 3,953.2 | -535.6 | +838.1% |
| EPS (Basic) | 15.46 | -2.08 | +843.3% |
| EPS (Diluted) | 15.32 | -2.08 | +836.5% |
| Wtd Avg Shares (Basic) | 255.7 | 257.9 | -0.9% |
| Wtd Avg Shares (Diluted) | 258 | 257.9 | 0.0% |
| Research & Development (FY) | — | — | — |
Show Collaborative Arrangements by Agreement [Axis] breakouts |
|||
| CRISPR JDCA | 62.2 | 31.6 | +96.8% |
| General & Administrative (FY) | — | — | — |
Show Business Segments breakouts |
|||
| Pharmaceuticals | 650.3 | 625.8 | +3.9% |
| Comprehensive Income | 3,809.5 | -393.5 | +1068.1% |
| Other Comprehensive Income | -143.7 | 142.1 | -201.1% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent | -198.1 | 136 | -245.7% |
| Accumulated Net Unrealized Investment Gain Loss | 26.9 | -2.5 | +1176.0% |
| Accumulated Other Comprehensive Income | -143.7 | 142.1 | -201.1% |
| Accumulated Translation Adjustment | 27.5 | 8.6 | +219.8% |
| Foreign Currency Transaction Gain Loss Before Tax | 13.7 | 27.3 | -49.8% |
Balance Sheet
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 5,084.8 | 4,569.6 | +11.3% |
| Marketable Securities (Current) | 1,523.3 | 1,546.3 | -1.5% |
| Accounts Receivable | 2,052.8 | 1,609.4 | +27.6% |
| Inventory | 1,686.8 | 1,205.4 | +39.9% |
| Prepaid Expenses & Other Current Assets | 853.3 | 665.7 | +28.2% |
| Total Current Assets | 11,201 | 9,596.4 | +16.7% |
| Non-Current Assets | |||
| Goodwill | 1,088 | 1,088 | 0.0% |
| Deferred Tax Assets | 2,897.9 | 2,331.1 | +24.3% |
| Operating Lease Right-of-Use Assets | 1,562.7 | 1,356.8 | +15.2% |
Show Real Estate And Accumulated Depreciation Description Of Property breakouts |
|||
| Fan Pier Leases [Member] | 847.9 | — | — |
| Jeffrey Leiden Center for Biologics, Cell and Genetic Therapies Campus | 296.7 | — | — |
| Marketable Securities (Non-Current) | 5,712.3 | 5,107.9 | +11.8% |
| Other Non-Current Assets | 1,236.6 | 999.3 | +23.7% |
| Total Assets | 25,643 | 22,533.2 | +13.8% |
| Intangible Assets (Q) | — | — | — |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Employment Contracts | 3.7 | 6.2 | -40.3% |
| Marketing Related Intangible Assets | 195.9 | 216.1 | -9.3% |
| Other Assets | |||
| Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | 1,520.3 | 1,227.8 | +23.8% |
| Intangible Assets Net Excluding Goodwill | 424.2 | 825.9 | -48.6% |
| Current Liabilities | |||
| Accounts Payable | 461.7 | 413 | +11.8% |
| Accrued Liabilities | 2,971.2 | 2,788.6 | +6.5% |
| Other Liabilities Current | 428.3 | 363 | +18.0% |
| Total Current Liabilities | 3,861.2 | 3,564.6 | +8.3% |
| Non-Current Liabilities | |||
| Operating Lease Liabilities | 1,846.5 | 1,544.4 | +19.6% |
Show Real Estate And Accumulated Depreciation Description Of Property breakouts |
|||
| Fan Pier Leases [Member] | 1 | — | — |
| Jeffrey Leiden Center for Biologics, Cell and Genetic Therapies Campus | 296.7 | — | — |
| Other Non-Current Liabilities | 1,269.5 | 1,014.6 | +25.1% |
| Total Liabilities | 6,977.2 | 6,123.6 | +13.9% |
| Stockholders' Equity | |||
| Common Stock | 2.5 | 2.6 | -3.8% |
| Additional Paid In Capital Common Stock | 5,119.2 | 6,672.4 | -23.3% |
| Accumulated Other Comprehensive Income | -15.9 | 127.8 | -112.4% |
| Retained Earnings | 13,560 | 9,606.8 | +41.2% |
| Total Stockholders' Equity | 18,665.8 | 16,409.6 | +13.7% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent | -87.1 | 111 | -178.5% |
| Accumulated Net Unrealized Investment Gain Loss | 34 | 7.1 | +378.9% |
| Accumulated Other Comprehensive Income | -15.9 | 127.8 | -112.4% |
| Accumulated Translation Adjustment | 37.2 | 9.7 | +283.5% |
| Additional Paid In Capital | 5,119.2 | 6,672.4 | -23.3% |
| Common Stock | 2.5 | 2.6 | -3.8% |
| Retained Earnings | 13,560 | 9,606.8 | +41.2% |
| Total Liabilities & Equity | 25,643 | 22,533.2 | +13.8% |
Cash Flow Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Stock-Based Compensation | 685.9 | 698.5 | -1.8% |
| Depreciation & Amortization | 209.8 | 207.2 | +1.3% |
| Increase Decrease In Other Deferred Liability | -510.8 | -348.8 | -46.4% |
| Other Non-Cash Items | 113.4 | 0.9 | +12500.0% |
| Change in Accounts Receivable | -347.3 | -99.3 | -249.7% |
| Change in Inventory | -524.2 | -517.3 | -1.3% |
| Change in Prepaid & Other Assets | -396 | -200.3 | -97.7% |
| Change in Accounts Payable | 36.8 | 49.5 | -25.7% |
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | -116.9 | 212.9 | -154.9% |
| Increase Decrease In Other Operating Liabilities | 148.5 | 39.7 | +274.1% |
| Net Cash from Operations | 3,631.4 | -492.6 | +837.2% |
| Deferred Income Taxes | -510.8 | -348.8 | -46.4% |
| Investing Activities | |||
| Purchases of Investments | -6,396.5 | -7,438.2 | +14.0% |
| Proceeds From Sale And Maturity Of Available For Sale Securities | 5,897.4 | 4,465.6 | +32.1% |
| Capital Expenditures | -437.6 | -297.7 | -47.0% |
| Proceeds From Sale Of Equity Securities Fv Ni | 16 | — | — |
| Other Investing Activities | -24.7 | -54 | +54.3% |
| Net Cash from Investing | -945.4 | -3,770 | +74.9% |
| Financing Activities | |||
| Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options | 127.7 | 114.6 | +11.4% |
| Share Repurchases | -2,017.4 | -1,177.1 | -71.4% |
| Tax Withholding for Share Compensation | -369.9 | -405 | +8.7% |
| Finance Lease Principal Payments | -5.4 | -33.6 | +83.9% |
| Proceeds From Payments For Other Financing Activities | 3.7 | 6.2 | -40.3% |
| Net Cash from Financing | -2,261.3 | -1,494.9 | -51.3% |
| Supplemental | |||
| Income Taxes Paid | 1,566.7 | 1,082.1 | +44.8% |
| Interest Paid | 12.4 | 30.5 | -59.3% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 90.9 | -42.6 | +313.4% |
| Net Change in Cash | 515.6 | -5,800.1 | +108.9% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 5,087.8 | 4,572.2 | +11.3% |
Values in millions USD. Source: SEC EDGAR 10-K filing.